The TransAct team has executed transactions in Health Care - Life Sciences - Chemicals for a large set of global and medium-sized Corporate Clients, Venture Capital and Private Equity firms worth several billions of Euros in enterprise value.

The profiled selected reference transactions are aimed to provide an overview of our services breadth within our middle-market and sector transactions focus.

Reference Transaction 1

Exit Management for Private Equity

TransAct advised Auctus Capital Partners and Lead Equities in selling the Active Pharmaceuticals niches specialist PharmaZell to Ergon Capital Partners in a competitive process. The merged entity with an existing portfolio company Farmabios SpA created a ~€125 million revenues business renamed Zellbios with manufacturing facilities in Germany, Italy and India and global sales and marketing reach to the leading originator and generics pharmaceuticals companies. Reference Transaction Press Release PDF

Reference Transaction 2

Drug Candidate Licensing

TransAct advised Medigene – a publicly listed biotechnology company – in executing an exclusive global license agreement with Dr. Falk Pharma for the development and commercialization of its drug candidate RhuDex® for indications in hepatology and gastroenterology. Dr. Falk Pharma assumed responsibility and all costs relating to the clinical development and marketing of RhuDex® in these therapeutic areas. Medigene received an upfront payment plus future milestone payments and royalties. Medigene retained the rights for RhuDex® in the indication areas rheumatoid arthritis, psoriasis and other autoimmune diseases. Reference Transaction Press Release PDF

Reference Transaction 3

Joint Venture Strategic Partnership

TransAct advised DR. KADE (Germany) and Besins Healthcare (Thailand / Belgium) in creating an industry leader by combining their prescription medicine product portfolios in the fields of Gynaecology, Andrology and Urology in Germany within the joint venture DR. KADE / BESINS Pharma. TransAct helped to initiate the transaction and advised DR. KADE throughout the entire process in a second transforming transaction following the acquisition by DR. KADE of the German OTC portfolio of Takeda and which we also exclusively advised. As a result of both transactions DR. KADE has developed to a Rx / OTC leader in the female and male health segments and selected niches. Reference Transaction Press Release PDF

Reference Transaction 4

Acquisition and Licensing of OTC Products Rights

TransAct advised DR. KADE in acquiring the German OTC products portfolio of Takeda (formerly Nycomed / Altana) in a competitive bidding process managed by the sellers. The portfolio includes some of Germany’s most well-known OTC brands such as Sanostol, Riopan, Faktu, Buer and a license to the OTC version of the proton pump inhibitor Pantozol Control. Furthermore, the transaction entailed structuring a long-term product supply agreement whereby Takeda provides manufacturing services from German and Poland based facilities to DR. KADE. Reference Transaction Press Release PDF

Reference Transaction 5

Pharmaceuticals Manufacturing Site Carve-out

TransAct advised AstraZeneca in structuring an asset carve-out of its German API, formulation and packing manufacturing facility, spun-out in a competitive process to CordenPharma, a SPV created and funded by International Chemicals Investors. The transaction also entailed structuring product procurement commitments by AstraZeneca to enable transitioning the captive site to a competitive contract manufacturer for third parties. Reference Transaction Press Release PDF

Reference Transaction 6

R&D Site Spin-out

TransAct advised Covance, the drug development business of LabCorp in spinning-out its pre-clinical R&D site in Alnwick, UK to ARC Trinova, a SPV formed by Shott Trinova LLP. After buying the sites in Alnwick and Porcheville as part of a broader partnership with Sanofi, TransAct was mandated to assist in consolidating Covance’s European site network. Reference Transaction Press Release PDF

Reference Transaction 7

VC backed Portfolio Company Spin-out

TransAct advised Protagen AG, a venture capital backed company including MIG Fonds as lead investor, in spinning-out Protagen Protein Services - an internationally renowned specialist for protein characterization and biosimilar comparability - in a competitive process to Zukunftsfonds Heilbronn, which merged the business with one of its portfolio firms. The capital injection generated by this transaction enables Protagen AG to further fund its development program for novel diagnostics on a non-dilutive basis to its shareholders. Reference Transaction Press Release PDF

Reference Transaction 8

Product Partnering

TransAct advised AstraZeneca in sourcing, structuring and negotiating a promotion and marketing agreement with Actelion in the German market for Tracleer, a globally leading therapeutic for pulmonary arterial hypertension. Reference Transaction Press Release PDF